725 related articles for article (PubMed ID: 21827214)
1. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of tyrosine kinase inhibitors.
van Erp NP; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2009 Dec; 35(8):692-706. PubMed ID: 19733976
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding JF; Zhong DF
Yao Xue Xue Bao; 2013 Jul; 48(7):1080-90. PubMed ID: 24133973
[TBL] [Abstract][Full Text] [Related]
5. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Heine A; Schilling J; Grünwald B; Krüger A; Gevensleben H; Held SA; Garbi N; Kurts C; Brossart P; Knolle P; Diehl L; Höchst B
Cancer Immunol Immunother; 2016 Mar; 65(3):273-82. PubMed ID: 26786874
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
[TBL] [Abstract][Full Text] [Related]
9. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
10. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Narjoz C; Favre A; McMullen J; Kiehl P; Montemurro M; Figg WD; Beaune P; de Waziers I; Rochat B
PLoS One; 2014; 9(5):e95532. PubMed ID: 24819355
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
12. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
13. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
16. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
17. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
Tullemans BME; Veninga A; Fernandez DI; Aarts MJB; Eble JA; van der Meijden PEJ; Heemskerk JWM; Kuijpers MJE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681859
[TBL] [Abstract][Full Text] [Related]
18. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Kitagawa D; Gouda M; Kirii Y; Sugiyama N; Ishihama Y; Fujii I; Narumi Y; Akita K; Yokota K
J Biochem; 2012 Jan; 151(1):47-55. PubMed ID: 21880693
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors.
Trent J; Molimard M
Semin Oncol; 2011 Apr; 38 Suppl 1():S28-33. PubMed ID: 21419933
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Andriamanana I; Gana I; Duretz B; Hulin A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
